(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData, Phase II drugs for Merkel Cell Carcinoma have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Nivolumab + relatlimab)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Nivolumab + relatlimab) overview

Nivolumab and Relatlimab-rmbw (Opdualag) is a fixed-dose combination of two IgG4 kappa monoclonal antibodies (mAbs). It is formulated as solution, concentrate solution for intravenous route of administration. Opdualag is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

BMS-986213, a fixed dose combination of nivolumab and relatlimab is under development for the treatment of hepatocellular carcinoma, refractory solid tumors, non-small cell lung cancer (NSCLC), recurrent or refractory classical Hodgkin lymphoma and b-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), peripheral t-cell lymphomas (PTCL) and primary mediastinal B-cell lymphoma, gastric cancer, adenocarcinoma of the gastroesophageal junction, metastatic hepatocellular carcinoma, metastatic uveal melanoma, merkel cell carcinoma, head and neck squamous cell carcinoma (HNSC) and cutaneous squamous cell carcinoma and metastatic colorectal cancer. The drug candidate is formulated as solution administered by intravenous route. It is a monoclonal antibody directed against lymphocyte activation gene 3 protein (LAG3) and programmed cell death protein 1 (PD1). It is developed based on ENHANZE (recombinant human hyaluronidase PH20 enzyme (rHuPH20) Technology.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of (Nivolumab + relatlimab)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.